Skip to main content
SpringerLink
Log in

Paroxetine Controlled Release

  • Adis Drug Profile
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

  • ▴ A controlled-release (CR) formulation of the SSRI paroxetine has been developed. This CR formulation delays the release of paroxetine until the tablet has passed through the stomach; the drug is then released over 4–5 hours.

  • ▴ In well designed placebo-controlled trials in patients with major depressive disorder (including a study in the elderly), social anxiety disorder or premenstrual dysphoric disorder (PMDD), paroxetine CR was consistently superior to placebo with regards to primary endpoints (i.e. mean Hamilton Rating Scale for Depression total score [major depressive disorder], Liebowitz social anxiety scale total score and Clinical Global Impressions-Global Improvement score [social anxiety disorder] and Visual Analogue Scale-Mood score [PMDD]). The duration of treatment was 12 weeks or, in PMDD, over three menstrual cycles (intermittent or continuous administration).

  • ▴ Paroxetine CR also demonstrated efficacy in three well designed studies in patients with panic disorder with or without agoraphobia.

  • ▴ Paroxetine CR was generally well tolerated in clinical trials, with an adverse-event profile typical of SSRIs, although recipients of paroxetine CR experienced significantly less nausea than recipients of immediate-release paroxetine in the first week of treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Bauer M, Whybrow PC, Angst J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, Part 2: maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. World J Biol Psychiatry 2002; 3: 69–86

    Article  PubMed  Google Scholar 

  2. Grady-Weliky TA. Premenstrual dysphoric disorder. N Engl J Med 2003 Jan 30; 348: 433–8

    Article  PubMed  Google Scholar 

  3. American Psychiatric Association. Practice guideline for the treatment of patients with panic disorder. Am J Psychiatry 1998 May; 155(5 Suppl.): 1–34

    Google Scholar 

  4. Ballenger JC, Davidson JRT, Lecrubier Y, et al. Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 1998; 59 Suppl. 17: 54–60

    Google Scholar 

  5. Golden RN, Perera P, Holdsworth S, et al. Tolerability of controlled and immediate release SSRIs in the treatment of major depression and anxiety disorders [poster]. American Psychiatric Association 2003 Annual Meeting; 2003 May 17–22; San Francisco

  6. Wagstaff AJ, Cheer SM, Matheson AJ, et al. Paroxetine: an update of its use in psychiatric disorders in adults. Drugs 2002; 62(4): 655–703

    Article  PubMed  CAS  Google Scholar 

  7. Rapaport MH, Schneider LS, Dunner DL, et al. Efficacy of controlled-release paroxetine in the treatment of late-life depression. J Clin Psychiatry 2003 Sep; 64(9): 1065–74

    Article  PubMed  CAS  Google Scholar 

  8. Dechant KL, Clissold SP. Paroxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 1991 Feb; 41(2): 225–53

    Article  PubMed  CAS  Google Scholar 

  9. Foster RH, Goa KL. Paroxetine: a review of its pharmacology and therapeutic potential in the management of panic disorder. CNS Drugs 1997; 8(2): 163–88

    Article  CAS  Google Scholar 

  10. Gunasekara NS, Noble N, Benfield P. Paroxetine: an update on its pharmacology and therapeutic use in depression and a review of its use in other disorders. Drugs 1998; 55(1): 85–120

    Article  PubMed  CAS  Google Scholar 

  11. Prakash A, Foster RH. Paroxetine: a review of its use in social anxiety disorder. CNS Drugs 1999; 12(2): 151–69

    Article  CAS  Google Scholar 

  12. Owens MJ, Knight DL. Human monoamine transporter binding profile of the SSRIs [abstract no. NR325]. American Psychiatric Association 2000 Annual Meeting; 2000 May 13–18; Chicago

  13. Blier P, de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci 1994; 15: 220–6

    Article  PubMed  CAS  Google Scholar 

  14. Chaput Y, de Montigny C, Blier P. Presynaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments: an in vivo electrophysiologic study in the rat. Neuropsychopharmacology 1991; 5(4): 219–29

    PubMed  CAS  Google Scholar 

  15. Gilmor ML, Owens MJ, Nemeroff CB. Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine. Am J Psychiatry 2002 Oct; 159(10): 1702–10

    Article  PubMed  Google Scholar 

  16. Thomas DR, Nelson DR, Johnson AM. Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology (Berl) 1987; 93: 193–200

    Article  CAS  Google Scholar 

  17. Röschke J, Kögel P, Schlösser R, et al. Analysis of sleep EEG microstructure in subchronic paroxetine treatment of healthy subjects. Psychopharmacology (Berl) 1997; 132: 44–9

    Article  Google Scholar 

  18. Saletu B, Frey R, Krupka M, et al. Sleep laboratory studies on the single-dose effects of serotonin reuptake inhibitors paroxetine and fluoxetine on human sleep and awakening qualities. Sleep 1991 Oct; 14(5): 439–47

    PubMed  CAS  Google Scholar 

  19. Schlösser R, Röschke J, Rossbach W, et al. Conventional and spectral power analysis of all-night sleep EEG after subchronic treatment with paroxetine in healthy male volunteers. Eur Neuropsychopharmacol 1998; 8: 273–8

    Article  PubMed  Google Scholar 

  20. Hicks JA, Argyropoulos SV, Rich AS, et al. Randomised controlled study of sleep after nefazodone or paroxetine treatment in out-patients with depression. Br J Psychiatry 2002 Jun; 180: 528–35

    Article  PubMed  CAS  Google Scholar 

  21. Sharpley AL, Williamson DJ, Attenburrow MEJ, et al. The effects of paroxetine and nefazodone on sleep: a placebo controlled trial. Psychopharmacology (Berl) 1996; 126: 50–4

    Article  CAS  Google Scholar 

  22. Hawley CJ, McPhee S, Quick SJ, et al. A review of the pschomotor effects of paroxetine. Int Clin Psychopharmacol 1997; 12(1): 13–8

    Article  PubMed  CAS  Google Scholar 

  23. Warrington SJ, Lewis Y. Cardiovascular effects of antidepressants: studies of paroxetine in healthy men and depressed patients. Int Clin Psychopharmacol 1992 Jun; 6 Suppl. 4: 59–64

    Article  Google Scholar 

  24. Pollock BG, Laghrissi-Thode F, Wagner WR. Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. J Clin Psychopharmacol 2000; 20(2): 137–40

    Article  PubMed  CAS  Google Scholar 

  25. Musselman DL, Marzec UM, Manatunga A, et al. Platelet reactivity in depressed patients treated with paroxetine: preliminary findings. Arch Gen Psychiatry 2000 Sep; 57: 875–82

    Article  PubMed  CAS  Google Scholar 

  26. GlaxoSmithKline. Paxil CR™ (paroxetine hydrochloride) controlled-release tablets prescribing information [online]. Available from URL: http://www.gsk.com [Accessed 2004 Mar 1]

  27. Golden RN, Nemeroff CB, McSorley P, et al. Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression. J Clin Psychiatry 2002 Jul; 63(7): 577–84

    Article  PubMed  CAS  Google Scholar 

  28. Trivedi M, Dillingham K, Pitts CD. Paroxetine CR efficacy and tolerability at low doses in the treatment of major depression [abstract no. 6244]. The World Journal of Biological Psychiatry 2004; 5 Suppl. 1: 94 plus poster presented at the World Federation of Societies of Biological Psychiatry/International Congress of Biological Psychiatry; 2004 Feb 9–13; Sydney

    Google Scholar 

  29. St Lambert J, Rasmussen S, Ruggiero LD, et al. Efficacy of controlled-release paroxetine in the treatment of patients with social anxiety disorder [abstract no. NR793 plus poster]. American Psychiatric Association 2003 Annual Meeting; 2003 May 17–22; San Francisco

  30. Cohen LS, Soares CN, Yonkers KA, et al. Paroxetine controlled release is effective in treating premenstrual dysphoric disorder [abstract]. Obstet Gynecol 2003 Apr; 101(4 Suppl.): 111S

    Google Scholar 

  31. Gee M, Bellew KM, Holland FJ, et al. Luteal phase dosing of paroxetine controlled release is effective in treating PMDD [abstract no. NR760 pus poster]. American Psychiatric Association 2003 Annual Meeting; 2003 May 17–22; San Francisco

  32. Yonkers KA, Bellew KM, Rolfe TE, et al. Pooled analysis of three large clinical trials in the treatment of PMDD [abstract no. NR677 plus poster]. American Psychiatric Association 2003 Annual Meeting; 2003 May 17–22; San Francisco

  33. American Psychiatric Association. Diagnostic and statistic manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994

    Google Scholar 

  34. Bellew KM, Cohen LS, St Lambert J, et al. Long-term treatment of PMDD [abstract no. NR676 plus poster]. American Psychiatric Association 2003 Annual Meeting; 2003 May 17–22; San Francisco

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland, 1311, New Zealand

    Lynne M. Bang & Gillian M. Keating

Authors
  1. Lynne M. Bang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gillian M. Keating
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gillian M. Keating.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bang, L.M., Keating, G.M. Paroxetine Controlled Release. CNS Drugs 18, 355–364 (2004). https://doi.org/10.2165/00023210-200418060-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-200418060-00003

Keywords

Search

Navigation